Inhibikase Therapeutics, Inc. (IKT)
NasdaqCM · USD · Healthcare · Biotechnology
$1.52 (-4.40%) as of
Key statistics
- Market cap
- 212.09M
- Forward P/E
- -3.62
- EPS (TTM)
- -0.4100
- Dividend yield
- 0.00%
- 52-week range
- 1.3300 – 2.6100
- Beta
- 0.90
- Profit margin
- 0.00%
- Analyst target
- $5.55
- Volume
- 860.47k
About Inhibikase Therapeutics, Inc.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Wilmington, DE, United States
- Employees
- 35
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.